Gleeson Michael 4
4 · GenMark Diagnostics, Inc. · Filed Apr 16, 2021
Insider Transaction Report
Form 4
Gleeson Michael
SVP, Sales
Transactions
- Exercise/Conversion
Common Stock
2021-04-14$13.17/sh+4,926$64,875→ 407,623 total - Exercise/Conversion
Stock Option (Right to Buy)
2021-04-14$10.89/sh−12,787$139,250→ 12,001 totalExercise: $10.89From: 2017-03-06Exp: 2023-03-06→ Common Stock (12,787 underlying) - Exercise/Conversion
Common Stock
2021-04-14$12.30/sh+9,954$122,434→ 402,697 total - Exercise/Conversion
Stock Option (Right to Buy)
2021-04-14$12.30/sh−9,954$122,434→ 5,118 totalExercise: $12.30From: 2018-03-06Exp: 2024-03-06→ Common Stock (9,954 underlying) - Exercise/Conversion
Common Stock
2021-04-14$10.89/sh+12,787$139,250→ 420,410 total - Exercise/Conversion
Stock Option (Right to Buy)
2021-04-14$13.17/sh−4,926$64,875→ 989 totalExercise: $13.17From: 2019-02-19Exp: 2025-02-19→ Common Stock (4,926 underlying)
Holdings
- 30,069(indirect: By Trust)
Common Stock
Footnotes (1)
- [F1]Mr. Gleeson is the trustee of the Michael William Gleeson 2012 Irrevocable Trust and has voting and dispositive power with respect to these shares. Mr. Gleeson disclaims beneficial ownership except to the extent of his pecuniary interest therein.